[{"id":"7bd9571b-58aa-4096-9e2d-0e1358581a79","acronym":"","url":"https://clinicaltrials.gov/study/NCT02965157","created_at":"2021-01-18T14:34:27.919Z","updated_at":"2024-07-02T16:37:27.607Z","phase":"Phase 1/2","brief_title":"Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma","source_id_and_acronym":"NCT02965157","lead_sponsor":"Beijing Biohealthcare Biotechnology Co.,Ltd","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CART20"],"overall_status":"Unknown status","enrollment":" Enrollment 15","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 01/01/2018","primary_completion_date":" 01/01/2018","study_txt":"","study_completion_date":"","last_update_posted":"2016-11-16"}]